eViralHepatitis Review, Volume 5, Issue 10

If your email client cannot read HTML emails, please visit our website

IMPORTANT E-MAIL DELIVERY INFORMATION: In order to view our newsletters in their entirety, please add our email address, news@johnshopkins.6cp.com, to your Contact List, Safe List or Address Book. This action should also ensure eViralHepatitis Review emails go directly to your Inbox.

Please do not reply to this email. To change/update your email address, please visit here.

Unsubscribe from this list.

Download PDF

RECOMMEND TO
A COLLEAGUE



	VOLUME 5 - ISSUE 10

Managing DAA Failures in Light of New HCV Regimen Approvals

Explain the risk of resistance development following unsuccessful HCV therapy with direct acting antivirals.
Discuss the impact DAA resistance and other negative predictors (for example, cirrhosis) may have on newly the approved retreatment options.
Describe effective retreatment strategies for patients who have previously failed HCV DAA therapy.

Guest Faculty Disclosure
Dr. Wyles has disclosed that he has served as a consultant and/or advisor to AbbVie, Inc., Gilead Sciences, Inc., and Merck & Co., Inc. He has also received grant and/or research funding from AbbVie, Gilead Sciences, and Merck & Co.

Unlabeled/Unapproved Uses
In his discussion today, Dr. Wyles has indicated that he will make reference to the unlabeled use of ribavirin with the sofosbuvir/velpatasvir/voxilaprevir combination, although such use is recommended in the current HCV treatment guidelines.


		MEET THE AUTHOR



				David L. Wyles, MD Chief, Division of Infectious Diseases Denver Health Medical Center at the University of Colorado Denver, Colorado

Release Date:	Expiration Date:
November 30, 2017	November 29, 2019


		OTHER RESOURCES



		Download the podcast transcript Go to the companion newsletter

PROGRAM DIRECTORS

Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and
Gastroenterology/Hepatology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Raymond T. Chung, MD
Director of Hepatology and Liver Center
Vice Chief, Gastroenterology
Kevin and Polly Maroni Research Scholar
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Taryn Haselhuhn, BA, BSN, MSN, CRNP
Nurse Practitioner
The Johns Hopkins Hospital
Baltimore, Maryland



	CME/CE INFORMATION


	ACCREDITATION STATEMENT Physicians This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENT Physicians Podcast: The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. POLICY ON SPEAKER AND PROVIDER DISCLOSURE It is the policy of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the instructional materials.

	INTERNET CME/CE POLICY DISCLAIMER STATEMENT STATEMENT OF RESPONSIBILITY STATEMENT OF NEED	INTENDED AUDIENCE CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANTS HARDWARE & SOFTWARE REQUIREMENTS COMPLETE CME INFORMATION



All rights reserved - The Johns Hopkins University School of Medicine. Copyright 2017. This activity was developed in collaboration with DKBmed.